Merck Stock Targets $200 on Key Regulatory Milestones

Merck's stock has surged this year due to strong sales of its KEYTRUDA drug and upcoming regulatory milestones. Between September and October, the company faces several FDA decision deadlines for new drug applications, including WINREVAIR and WELIREG combinations. Additionally, Merck is set to release major data on its personalized cancer vaccine developed with Moderna at the ESMO conference in late October.

The success of these events could boost analyst price targets and push the stock toward $200, despite risks from KEYTRUDA patent expiration and recent acquisition charges. According to Pluang, investors should watch these catalysts closely as they could cause stock volatility in either direction.